A medicinal product containing only one of two active substances contained in an earlier product is not part of the global marketing authorisation and is, therefore, entitled to its own data ...
Biogen's multiple sclerosis business has been treading water and its best-selling med, Tecfidera, might just run up against early generics. But now, the company has its next launch—and, it hopes, ...
The multiple sclerosis field has grown increasingly competitive in recent years, but now Biogen is touting data the drugmaker believes will give its established Tecfidera an edge new rivals can’t ...
Mylan is offering dimethyl fumarate delayed-release capsules in dosage strengths of 120 mg and 240 mg. The product is the generic of Biogen’s Tecfidera capsules. It is indicated for the treatment of ...
Biogen Idec presented new data demonstrating the favorable efficacy, safety, and tolerability of Tecfidera (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis (RRMS). The data ...
The PTAB issued a Final Written Decision finding that Biogen’s patent on treating Multiple Sclerosis (“MS”) with a certain dose amount was not obvious because the clinical efficacy exhibited by ...
CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new data to support the consistent, long-term benefits of treatment with TECFIDERA® (dimethyl fumarate) over ...
WASHINGTON (Reuters) - U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback